Sign in Subscribe
Cancer research

Age-Based Classifications in AML Treatment May be Outdated

Strategic Insights

— 2 min read

An international study has revealed that age-based classifications in the treatment of acute myeloid leukemia (AML) may be overly simplistic and no longer reliable. Researchers from the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group analyzed data from 2,823 adult AML patients treated in the United States and Germany, uncovering nuanced age-related trends in genetic mutations and survival outcomes that challenge current clinical practices. The study suggests that age alone should not be a gatekeeper to potentially life-saving therapies, and that a more flexible, biology-driven approach to AML treatment and trial design is needed.

Key Takeaways:

  • The study analyzed data from 2,823 adult AML patients treated in the United States and Germany, making it the first large-scale, cross-continental study to analyze the mutational patterns and outcomes among patients of all age groups with AML.
  • The study found no clear age threshold that could biologically or prognostically separate patients into distinct groups, challenging the long-standing practice of using arbitrary age cut-offs, such as 60 or 65 years, to guide treatment decisions.
  • Genetic mutations and survival outcomes varied continuously across the age spectrum, which is at odds with current clinical practices that use age-based classifications.
  • Survival outcomes declined steadily with age, even among patients classified as having favorable genetic risk, with patients aged 18 to 24 having a 5-year overall survival rate of 73%, compared to 21% for those aged 75 and older.
  • The study's findings highlight the need for a more flexible, biology-driven approach to AML treatment and trial design, rather than relying solely on age-based classifications.
  • The research also underscores the importance of considering molecular and genetic profiles rather than chronological age when tailoring treatments to individual patients, which may improve outcomes and expand access to novel therapies.

Statistics:

  • 2,823 adult AML patients were included in the study.
  • The study analyzed data from patients treated in the United States (CALGB/Alliance) and Germany (AMLCG).
  • The analysis included patients treated with frontline cytarabine-based chemotherapy between 1986 and 2017.
  • Molecular profiling was conducted using targeted sequencing platforms, and survival outcomes were assessed using the 2022 European LeukemiaNet (ELN) genetic-risk classification.
  • Survival outcomes declined steadily with age, from a 5-year overall survival rate of 73% for patients aged 18 to 24 to 21% for those aged 75 and older.
  • The study received funding from the National Cancer Institute, the Deutsche Jose Carreras Leukamie-Stiftung, the Bavarian Cancer Research Center, the Pelotonia Institute for Immuno-Oncology, the Coleman Leukemia Research Foundation, the Leukemia and Lymphoma Society, and the American Cancer Society.

Sources:

  • The study was published in Leukemia.
  • The study was funded by the National Cancer Institute to the Alliance for Clinical Trials in Oncology.
  • Additional funding came from the Deutsche Jose Carreras Leukamie-Stiftung, the Bavarian Cancer Research Center, the Pelotonia Institute for Immuno-Oncology, the Coleman Leukemia Research Foundation, the Leukemia and Lymphoma Society, and the American Cancer Society.

Read more